The present invention discloses novel non-natural and modified peptides acting as cannabinoid (CB) receptors ligands, especially CB1 and/or CB2, useful as modulators of its activity they are also described as a kit and a process in vitro for evaluating the binding to CB receptors, uses and pharmaceutical composition for modulating the CB receptors activity. The invention covers the non-natural peptide of SeqID:1 and those having at least 70% similarity related to the same, including as achievements specialty useful of the invention the non-natural peptides of SeqID:2, SeqID:3, SeqID:4, SeqID:5, SeqID:6.
